14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today EXEL ranks #16046 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$17.08 (-1.73%)

Volume: 2M

Closed: Jan 19, 2022

Hollow Logo Score: -4.540

Exelixis Stock Forecast

$17.08 (-1.73%)

Volume: 2M

Closed: Jan 19, 2022

Score Hollow Logo -4.540

Exelixis Stock News NASDAQ:EXEL

Corporate results, both actual and predicted, spurred trading in Monday''s pre-market action Read more
Bender Robert & Associates decreased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 96.4% during the third quarter, HoldingsChannel reports. The firm owned 2,626 shares of the biotechnology company’s stock after selling 70,589 shares during the quarter. Bender Robert & Associates’ holdings in Exelixis were worth $256,000 at the end of the most recent […] Read more
- Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ: ADAG ), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced achievement of a key milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate (ADC) candidates leveraging Adagene''s proprietary SAFEbody precision masking technology. Under the terms of a collaboration and licensing agreement established in early 2021, Adagene will receive a $3 million milestone payment for successful nomination of lead SAFEbody candidates for one of its collaboration programs. "We are extremely proud of successfully providing lead SAFEbody candidates to Exelixis following the start of our collaboration earlier this year. Exelixis'' selection of these lead candidates further validates our proprietary SAFEbody technology and highlights the prowess of our overall DPL platform," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer, and Chairman of Adagene. "Our SAFEbody masking technology is receiving clinical validation in our ongoing clinical trial from our anti-CTLA-4 monoclonal antibody program, and also marks a potential paradigm shift in the way a highly potent modality such as ADCs can be designed and developed, ultimately helping to improve the lives of patients suffering from cancer and other debilitating diseases." Under the terms of the agreement, Adagene received an upfront payment of $11 million and Exelixis can nominate two targets for development Read more

Huntington National Bank Boosts Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

09:46am, Wednesday, 22'nd Dec 2021 Dakota Financial News
Huntington National Bank raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 156.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,433 shares of the biotechnology companys stock after acquiring an additional 874 shares during the period. Huntington National Banks [] Read more

Peter Lamb Sells 47,500 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

10:16am, Sunday, 19'th Dec 2021 Transcript Daily
Exelixis, Inc. (NASDAQ:EXEL) EVP Peter Lamb sold 47,500 shares of Exelixis stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $17.44, for a total value of $828,400.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Peter Lamb [] Read more
Tandem Capital Management Corp ADV lessened its stake in Exelixis, Inc. (NASDAQ:EXEL) by 37.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,650 shares of the biotechnology company’s stock after selling 5,770 shares during the quarter. Tandem Capital Management Corp […] Read more

Exelixis Elects Jacqueline Wright to Its Board of Directors

01:00pm, Friday, 17'th Dec 2021 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that accomplished technology executive Jacqueline (Jacky) Wright has been elected to the companys Board of Directors. Ms. Wrights appointment took effect on December 16, 2021. Ms. Wright has decades of technology experience and is widely recognized for her expertise in digital transformation, both in the public and private sectors. She currently serves as Corporate Vice President & Chief Digital Officer, U.S. Read more

Contrasting ERYTECH Pharma (NASDAQ:ERYP) and Exelixis (NASDAQ:EXEL)

10:16pm, Thursday, 16'th Dec 2021 Dakota Financial News
ERYTECH Pharma (NASDAQ:ERYP) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares ERYTECH Pharma and Exelixis’ net margins, return on equity and return on assets. […] Read more
Stephens Investment Management Group LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 17.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,432,147 shares of the biotechnology companys stock after buying an additional 508,967 shares during the period. [] Read more
– STELLAR-002 is second trial to evaluate XL092, a next-generation tyrosine kinase inhibitor, in advanced cancers – ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 15, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of STELLAR-002, a phase 1b trial evaluating Read more

Cambiar Investors LLC Reduces Position in Exelixis, Inc. (NASDAQ:EXEL)

03:44pm, Wednesday, 08'th Dec 2021 Dakota Financial News
Cambiar Investors LLC lessened its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.5% during the 3rd quarter, Holdings Channel reports. The firm owned 617,306 shares of the biotechnology companys stock after selling 2,939 shares during the quarter. Cambiar Investors LLCs holdings in Exelixis were worth $13,050,000 as of its most recent filing with the [] Read more
It''s been a feast for bulls operating on the daily timeframe, as exel has now gone up 4 of the past 5 days. The post Exelixis Inc (EXEL): Price Now Near $16.56; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News . Read more
Oregon Public Employees Retirement Fund cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 105,649 shares of the biotechnology companys stock after selling 739 shares during the quarter. Oregon Public Employees Retirement Funds holdings [] Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE